Med. praxi. 2011;8(12):500-508

Management of hypertension in specific settings and in the presence of comorbidities

prof.MUDr.Jan Bultas, CSc.
Ústav farmakologie 3. LF UK, Praha

The management of hypertension lies largely in the hands of the general practitioner, with an occasional need to seek the help of a specialist.

However, the primary care physician must treat a patient who has many comorbidities with their own specific features. An optimal therapeutic

approach to a hypertensive patient is determined by a number of factors: age, comorbidities, actual level of blood pressure, medications for

comorbidities, patient compliance and numerous other factors. The selection of the most appropriate drug which will best contribute to improving

the patient’s prognosis and, at the same time, will be well tolerated, depends on recognizing and observing these factors. The present

paper presents the current views on the management of hypertension in the elderly, diabetics, nephrological patients and cardiac patients

with heart failure or valvular heart disease, and on the management of hypertension in pregnancy or in those with resistant hypertension

or with hypertensive crisis. The above-mentioned may suggest that the management of hypertension is something of a puzzle for doctors;

fortunately, however, basic principles can be applied to the majority of situations and relatively few drugs are required. Nevertheless, there

are significant differences even among commonly used antihypertensive drugs not only between classes, but also within drug classes.

hypertension.

Keywords: arterial hypertension, pharmacotherapy, diabetes mellitus, heart failure, valvular heart disease, pregnancy, resistant

Published: December 15, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bultas J. Management of hypertension in specific settings and in the presence of comorbidities. Med. praxi. 2011;8(12):500-508.
Download citation

References

  1. Khan M, et al. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006; 174(12): 1737-1742. Go to original source... Go to PubMed...
  2. Kuo SW, et al. Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes Am J Hypertens. 2003; 16(8): 623-628. Go to original source... Go to PubMed...
  3. Kang S, et al. A systematic review and meta-analysis of the efficacy and safety of a fixed, low-dose perindopril-indapamide combination as first-line treatment of hypertension. Clin Ther. 2004; 26(2): 257-270. Go to original source... Go to PubMed...
  4. MacKinnon M, et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis. 2007; 49(3): 497. Go to original source... Go to PubMed...
  5. Sever PS, et al. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. J Hypertens. 2009; 27(5): 947-954. Go to original source... Go to PubMed...
  6. Norris S, et al. Drug Class Review: Direct Renin Inhibitors, Angiotensin Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers: Final Report [Internet].
  7. Moser M, et al. Resistant or difficult-to-control hypertension, N Engl J Med, 2006; 355: 385-392. Go to original source... Go to PubMed...
  8. Verdecchia P et Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet. 2009 15; 374(9689): 525-533. Go to original source... Go to PubMed...
  9. Stamler J. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993; 16(2): 434-444. Go to original source... Go to PubMed...
  10. Stump CS, et al. Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc. 2006; 81(6): 796-806. Go to original source... Go to PubMed...
  11. Elliott WJ, et al. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007; 369(9557): 201-207. Go to original source... Go to PubMed...
  12. Bramlage P, et al. Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care. BMC Cardiovasc Disord. 2008; 8: 30. Go to original source... Go to PubMed...
  13. Iwanaga T, et al. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther. 2007; 320(1): 211-217. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.